Potent synergistic effect of doxycycline with fluconazole against Candida albicans is mediated by interference with iron homeostasis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3785-3796

  Fiori, Alessandro ^a,b   Van Dijck, Patrick ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; DOXYCYCLINE; FLUCONAZOLE; FUNGAL PROTEIN; IRON;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TOLERANCE; FUNGAL CELL; FUNGAL GENE; FUNGUS GROWTH; FUNGUS MUTANT; GROWTH INHIBITION; HOMEOSTASIS; IRON CHELATION; IRON DEPLETION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

CANDIDA ALBICANS; CYTOCHROME P-450 ENZYME SYSTEM; DOXYCYCLINE; DRUG SYNERGISM; FLUCONAZOLE; HOMEOSTASIS; IRON; MICROBIAL SENSITIVITY TESTS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 84862576549     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06017-11     Document Type: Article

References (62)

1. Akins RA. 2005. An update on antifungal targets and mechanisms of resistance in Candida albicans. Med. Mycol. 43:285-318.
2. Almeida RS, et al. 2008. The hyphal-associated adhesin and invasin Als3 of Candida albicans mediates iron acquisition from host ferritin. PLoS Pathog. 4:e1000217. doi:10.1371/journal.ppat.1000217.
3. Backen AC, et al. 2000. Evaluation of the CaMAL2 promoter for regulated expression of genes in Candida albicans. Yeast 16:1121-1129.
4. Balashov SV, Park S, Perlin DS. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50:2058-2063.
5. Barelle CJ, et al. 2004. GFP as a quantitative reporter of gene regulation in Candida albicans. Yeast 21:333-340.
6. Berman J, Sudbery PE. 2002. Candida albicans: a molecular revolution built on lessons from budding yeast. Nat. Rev. Genet. 3:918-930.
7. Braun BR, et al. 2005. A human-curated annotation of the Candida albicans genome. PLoS Genet. 1:36-57.
8. Canton E, et al. 2003. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn. Microbiol. Infect. Dis. 45:203-206.
9. Chopra I, Roberts M. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65:232-260.
10. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Coste A, et al. 2007. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot. Cell 6:1889-1904.
12. Craven RJ, Mallory JC, Hand RA. 2007. Regulation of iron homeostasis mediated by the heme-binding protein Dap1 (damage resistance protein 1) via the P450 protein Erg11/Cyp51. J. Biol. Chem. 282:36543-36551.
13. Cruz MC, et al. 2002. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J. 21:546-559.
14. Du W, Coaker M, Sobel JD, Akins RA. 2004. Shuttle vectors for Candida albicans: control of plasmid copy number and elevated expression of cloned genes. Curr. Genet. 45:390-398.
15. Enjalbert B, et al. 2009. A multifunctional, synthetic Gaussia princeps luciferase reporter for live imaging of Candida albicans infections. Infect. Immun. 77:4847-4858.
16. Ernst EJ. 2005. Susceptibility testing methods of antifungal agents. Methods Mol. Med. 118:3-12.
17. Fonzi WA, Irwin MY. 1983. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728.
18. Gietz RD, Sugino A. 1988. New yeast-Escherichia coli shuttle vectors constructed with in vitro mutagenized yeast genes lacking six-base pair restriction sites. Gene 74:527-534.
19. Gillum AM, Tsay EY, Kirsch DR. 1984. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol. Gen. Genet. 198:179-182.
20. Grenier D, Huot MP, Mayrand D. 2000. Iron-chelating activity of tetracyclines and its impact on the susceptibility of Actinobacillus actinomycetemcomitans to these antibiotics. Antimicrob. Agents Chemother. 44:763-766.
21. Griffin MO, Ceballos G, Villarreal FJ. 2011. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol. Res. 63:102-107.
22. Heckman DS, et al. 2001. Molecular evidence for the early colonization of land by fungi and plants. Science 293:1129-1133.
23. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
24. Kelly SL, Arnoldi A, Kelly DE. 1993. Molecular genetic analysis of azole antifungal mode of action. Biochem. Soc. Trans. 21:1034-1038.
25. Kontoyiannis DP, Sagar N, Hirschi KD. 1999. Overexpression of Erg11p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 43:2798-2800.
26. Lan CY, et al. 2004. Regulatory networks affected by iron availability in Candida albicans. Mol. Microbiol. 53:1451-1469.
27. Lass-Florl C. 2009. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52:197-205.
28. Lepak A, et al. 2006. Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole. Antimicrob. Agents Chemother. 50:1311-1319.
29. Leuker CE, Sonneborn A, Delbruck S, Ernst JF. 1997. Sequence and promoter regulation of the PCK1 gene encoding phosphoenolpyruvate carboxykinase of the fungal pathogen Candida albicans. Gene 192:235-240.
30. Lewis RE. 2009. Overview of the changing epidemiology of candidemia. Curr. Med. Res. Opin. 25:1732-1740.
31. MacCallum DM, et al. 2010. Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. Antimicrob. Agents Chemother. 54:1476-1483.
32. Maesaki S, et al. 1998. Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains. J. Antimicrob. Chemother. 42:747-753.
33. Mallory JC, et al. 2005. Dap1p, a heme-binding protein that regulates the cytochrome P450 protein Erg11p/Cyp51p in Saccharomyces cerevisiae. Mol. Cell. Biol. 25:1669-1679.
34. Marchetti O, et al. 2000. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans . Antimicrob. Agents Chemother. 44:2373-2381.
35. Marr KA, White TC, van Burik JA, Bowden RA. 1997. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin. Infect. Dis. 25:908-910.
36. Miller CA, Martinat MA, Hyman LE. 1998. Assessment of aryl hydrocarbon receptor complex interactions using pBEVY plasmids: expression vectors with bi-directional promoters for use in Saccharomyces cerevisiae. Nucleic Acids Res. 26:3577-3583.
37. Morschhauser J. 2002. The genetic basis of fluconazole resistance development in Candida albicans. Biochim. Biophys. Acta 1587:240-248.
38. Murad AM, et al. 2000. CIp10, an efficient and convenient integrating vector for Candida albicans. Yeast 16:325-327.
39. Nakayama H, et al. 2000. Tetracycline-regulatable system to tightly control gene expression in the pathogenic fungus Candida albicans. Infect. Immun. 68:6712-6719.
40. Nelson ML. 1998. Chemical and biological dynamics of tetracyclines. Adv. Dent. Res. 12:5-11.
41. Noble SM, Johnson AD. 2007. Genetics of Candida albicans, a diploid human fungal pathogen. Annu. Rev. Genet. 41:193-211.
42. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
43. Odds FC, Abbott AB, Pye G, Troke PF. 1986. Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions. J. Med. Vet. Mycol. 24:305-311.
44. Oliver BG, et al. 2008. Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi. Microbiology 154:960-970.
45. Ostrosky-Zeichner L, et al. 2010. An insight into the antifungal pipeline: selected new molecules and beyond. Nat. Rev. Drug Discov. 9:719-727.
46. Park YN, Morschhauser J. 2005. Tetracycline-inducible gene expression and gene deletion in Candida albicans. Eukaryot. Cell 4:1328-1342.
47. Perea S, et al. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45:2676-2684.
48. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
49. Pfaller MA, Messer SA, Karlsson A, Bolmstrom A. 1998. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J. Clin. Microbiol. 36:2586-2589.
50. Pfaller MA, Sheehan DJ, Rex JH. 2004. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. 17:268-280.
51. Prasad T, Chandra A, Mukhopadhyay CK, Prasad R. 2006. Unexpected link between iron and drug resistance of Candida spp.: iron depletion enhances membrane fluidity and drug diffusion, leading to drug-susceptible cells. Antimicrob. Agents Chemother. 50:3597-3606.
52. Ramanan N, Wang Y. 2000. A high-affinity iron permease essential for Candida albicans virulence. Science 288:1062-1064.
53. Rusnak F, Mertz P. 2000. Calcineurin: form and function. Physiol. Rev. 80:1483-1521.
54. Ryan ME, et al. 2001. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. Curr. Med. Chem. 8:305-316.
55. Sanglard D, Ischer F, Koymans L, Bille J. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
56. Sanglard D, et al. 2003. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol. Microbiol. 48:959-976.
57. Sanglard D, et al. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
58. Selmecki A, et al. 2008. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol. Microbiol. 68:624-641.
59. Shapiro RS, Robbins N, Cowen LE. 2011. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol. Mol. Biol. Rev. 75:213-267.
60. Sherman F. 2002. Getting started with yeast. Methods Enzymol. 350:3-41.
61. Stettler S, et al. 1993. A general suppressor of RNA polymerase I, II and III mutations in Saccharomyces cerevisiae. Mol. Gen. Genet. 239:169-176.
62. White TC. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.